The Indian pharmaceutical sector showed mixed performance on January 28, 2026, as of around 10:13 AM IST. Broader market indices were positive, with the S&P BSE Sensex at 82,201.15 (up 0.42%) and Nifty 50 at 25,252.10 (up 0.30%). However, the Nifty Pharma index was around 21,788 levels based on recent data.
Key Gainers
- Alivus Life Sciences: up to 3.64% on NSE
- Dishman Carbogen Amcis: up to 3.18% on BSE
- Morepen Labs: up to 2.98% on BSE
- Senores Pharmaceuticals Ltd.: up to 2.60% on BSE
- Acutaas Chemicals: up to 2.36% on BSE
- Novartis: up 2.38% on BSE
- Sai Life Sciences Ltd.: up around 2.18% on BSE/NSE
- Pfizer: up around 1.31% on BSE
Key Losers
- RPG Life Sciences: down up to -8.88% on NSE
- Jubilant Industries: down up to -4.46% on NSE
- Indoco Remedies: down up to -4.27% on BSE
- Concord Biotech: down up to -3.86% on BSE
- Supriya Lifescience: down around -1.90% on BSE
- Max Healthcare Institute: down around -1.94% on BSE
- Sun Pharma: down around -1.14% on BSE/NSE
- Torrent Pharma: down around -1.23% on BSE
Other Notable Stocks
- Sun Pharmaceutical Industries (a major weight in Nifty Pharma): 1,620.55 on BSE (-1.14%), 1,620.80 on NSE (-1.10%)
- Cipla: 1,322.70 on BSE (0.75%)
- Divi’s Laboratories: 6,093.00 on BSE (0.58%)
- Dr. Reddy’s Laboratories: 1,232.55 on BSE (-0.60%)
- Alkem Laboratories: around 5,753-5,756 (near flat)
- Abbott India: around 27,660-27,700 (near flat)
Overall, the pharma sector had more stocks with minor gains or flat performance in the early session, but several mid- and small-cap names saw sharper declines. This reflects typical intraday volatility in the sector. For real-time updates or detailed analysis, refer to official sources like NSE, BSE, or financial platforms. Stock prices are subject to change and involve market risks. This is based on the data as of 10:13 AM IST on January 28, 2026, and is for informational purposes only.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
